Results 71 to 80 of about 22,552 (237)

Lupus Anticoagulant: Case-based External Quality Assessment

, 2009
Aims: A model for presenting case histories with quality assessment material is to be developed for the Dutch external quality assessment (EQA) scheme for blood coagulation testing.
Devreese, Katrien, van den Besselaar, A. M. H. P., de Groot, P. G., de Groot, Philip, Castel, A., Devreese, K. M. J., van den Besselaar, AM   +6 more
core   +1 more source

Interference from lupus anticoagulant on von Willebrand factor measurement in splenic marginal zone lymphoma:a case report

, 2015
We present a case concerning a patient with splenic marginal zone lymphoma (SMZL) and isolated prolonged activated partial thromboplastin time (aPTT) caused by lupus anticoagulant.
Nybo, Mads, Vinholt, Pernille J; id_orcid   +1 more
core   +1 more source

Degradomics for large‐scale mechanistic insights on proteases and proteolysis in human health

The FEBS Journal, EarlyView.
Proteolysis has an important role in human disease but remains relatively unexplored. Degradomics, the uncovering of proteolysis in tissues, cells, and proteins, uses mass spectrometry‐based terminomics to identify protein termini occurring therein (forward degradomics) and to define the actions of proteases (reverse degradomics).
Daniel R. Martin, Sumit Bhutada, Suneel S. Apte   +2 more
wiley   +1 more source

PREVALENCE OF LUPUS ANTICOAGULANT IN PATIENTS WITH CIRRHOSIS - RELATIONSHIP WITH BETA-2-GLYCOPROTEIN-I PLASMA-LEVELS

, 1994
We have previously demonstrated that patients with cirrhosis may be positive for lupus anticoagulant and anticardiolipin antibodies. The prevalence and clinical value of antiphospholipid antibodies in cirrhosis have never been described.
FERRO, Domenico, Giuseppa Tassone, Claudio Quintarelli, VIOLI, Francesco, VALESINI, Guido, BASILI, Stefania   +5 more
core   +1 more source

Design and Implementation of an Automated Interpretation Algorithm for Lupus Anticoagulant Functional Testing

International Journal of Laboratory Hematology, EarlyView.
ABSTRACT Introduction Lupus anticoagulant (LA) testing is essential, albeit complex, in the laboratory diagnosis of antiphospholipid syndrome (APS). Given the multi‐step workflow and the variability introduced by anticoagulant therapy, reagent differences, and interpretive approaches, result interpretation requires expert evaluation.
Chiara Novelli, Arianna Gatti, Flora Ierna, Elena Riccardi, Irene Cuppari   +4 more
wiley   +1 more source

Lupus anticoagulant-hypoprothrombinemia syndrome and catastrophic antiphospholipid syndrome in a patient with antidomain I antibodies

, 2016
Lupus anticoagulant-hypoprothrombinemia syndrome is a rare condition characterized by the association of acquired factor II deficiency and lupus anticoagulant. Contrary to classical antiphospholipid syndrome, it may cause severe life-threatening bleeding
Revuz, Sabine, de Laat, Bas, Zuily, Stephane, Wahl, Denis, de Maistre, Emmanuel, Levy, Bruno, Galland, Joris, Marie, Pierre-Yves, Regnault, Veronique, Mohamed, Shirine   +9 more
core   +1 more source

How I Investigate Borderline Prolonged aPTT: An Integrated Laboratory Approach to Mixing Studies and Factor Analysis

International Journal of Laboratory Hematology, EarlyView.
ABSTRACT Borderline prolongation of routine clotting assays—particularly the activated partial thromboplastin time (aPTT)—is a common interpretative challenge in laboratory hematology. These reproducible but mildly prolonged results often lie just beyond the upper reference limit and can trigger unnecessary follow‐up, delays, or misinterpretation ...
Nikolaos Androulakis, Eleni Nioti, Antonios Dilintas, Christina Kalpadakis   +3 more
wiley   +1 more source

Characteristics of childhood-onset Systemic Lupus Erythematosus in Cape Town, South Africa

, 2014
Includes bibliographical ...
Spittal, Graeme William
core  

Australian clinical practice guideline: diagnosis and treatment of idiopathic multicentric Castleman disease

Internal Medicine Journal, EarlyView.
Abstract Idiopathic multicentric Castleman disease (iMCD) is a rare condition. The pathogenesis is incompletely understood; however, interleukin‐6 (IL‐6) is a major mediator. The clinical presentation is heterogeneous, from mild constitutional symptoms to severe multi‐organ failure.
Dipti Talaulikar, Jun Yen Ng, Adam Bryant, Annmarie Bosco, Hugh C. Caterson, Pratyush Giri, Pravin Hissaria, Simon J. Harrison, Stephen Lade, Connull Leslie, Jacinta Perram, H. Miles Prince, Dejan Radeski, Maureen Rischmueller, Craig Wallington‐Gates, Nicholas Weber, Alberta Hoi   +16 more
wiley   +1 more source

Genetic risk variants implicate impaired maintenance and repair of periodontal tissues as causal for periodontitis—A synthesis of recent findings

Periodontology 2000, EarlyView.
AbstractPeriodontitis is a complex inflammatory disease in which the host genome, in conjunction with extrinsic factors, determines susceptibility and progression. Genetic predisposition is the strongest risk factor in the first decades of life. As people age, chronic exposure to the periodontal microbiome puts a strain on the proper maintenance of ...
Arne S. Schaefer, Luigi Nibali, Noha Zoheir, Niki M. Moutsopoulos, Bruno G. Loos   +4 more
wiley   +1 more source